Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival. The main goal of this work is to predict the toxicities derived from CPT-11 using artificial intelligence methods. The data for this study is conformed of 53 cycles of FOLFIRINOX, corresponding to patients with metastatic colorectal cancer. Supported by several demographic data, blood markers and pharmacokinetic parameters resulting from a non-compartmental pharmacokinetic study of CPT-11 and its metabolites (SN-38 and SN-38-G), we use machine learning techniques to predict high degrees of different toxicities (leukopenia, neut...
has been approved for use as a first- and second-line treat-ment for colorectal cancer. The response...
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is ...
Irinotecan is a topoisomerase I inhibitor prescribed to treat metastatic colorectal cancer. Its use ...
Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity...
The colorectal cancer ranks high among the malignant tumours in incidence and mortality and irinotec...
Colorectal cancer is the third leading cause of cancer-related deaths in the United States. Treatmen...
7noMachine learning (ML) algorithms have been used to forecast clinical outcomes or drug adverse eff...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
Introduction: Colorectal cancer is the fourth cancer with the highest incidence and the second with ...
Introduction: Colorectal cancer is the fourth cancer with the highest incidence and the second with ...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
Irinotecan is a topoisomerase I inhibitor prescribed to treat metastatic colorectal cancer. Its use ...
has been approved for use as a first- and second-line treat-ment for colorectal cancer. The response...
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is ...
Irinotecan is a topoisomerase I inhibitor prescribed to treat metastatic colorectal cancer. Its use ...
Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity...
The colorectal cancer ranks high among the malignant tumours in incidence and mortality and irinotec...
Colorectal cancer is the third leading cause of cancer-related deaths in the United States. Treatmen...
7noMachine learning (ML) algorithms have been used to forecast clinical outcomes or drug adverse eff...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
Introduction: Colorectal cancer is the fourth cancer with the highest incidence and the second with ...
Introduction: Colorectal cancer is the fourth cancer with the highest incidence and the second with ...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
International audiencePurposeThe aim of the present study was to characterize the pharmacokinetics o...
Irinotecan is a topoisomerase I inhibitor prescribed to treat metastatic colorectal cancer. Its use ...
has been approved for use as a first- and second-line treat-ment for colorectal cancer. The response...
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is ...
Irinotecan is a topoisomerase I inhibitor prescribed to treat metastatic colorectal cancer. Its use ...